What Is Genomic High-Risk Myeloma?
Although treatment of multiple myeloma has changed dramatically over time, there is still a subpopulation of patients who do not respond to treatments and are labeled as high risk. A combination of serum and genomic markers can be used to identify and stratify these patients according to association...
Main Authors: | Faith E. Davies, Brian A. Walker |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Hemato |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-6357/3/2/21 |
Similar Items
-
Genetic Abnormalities in Extramedullary Multiple Myeloma
by: Roisin McAvera, et al.
Published: (2023-07-01) -
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling
by: Rahul Banerjee, et al.
Published: (2023-10-01) -
Adoptive Immunotherapy and High-Risk Myeloma
by: Catherine Duane, et al.
Published: (2023-05-01) -
Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma
by: Chuanying Geng, et al.
Published: (2023-04-01) -
Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??
by: Kaloyannidis P, et al.
Published: (2022-10-01)